Omentin-1 vs IGF-1 LR3
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and IGF-1 LR3 (Insulin-like Growth Factor-1 Long R3) — benefits, dosing, side effects, research data, and where to buy.
| Property | Omentin-1 | IGF-1 LR3 |
|---|---|---|
| Category | Diabetes & Metabolic | Performance |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Insulin-like Growth Factor-1 Long R3 |
| Molecular Weight | ~35 kDa | 9,117 Da |
| Half-Life | hours | ~20-30 hours |
| Amino Acids | 313 | 83 |
| Typical Dose | No approved human dose; research use only | 20-100 mcg |
| Route | IV|SC | IM / SC |
| Purity | ≥98% | — |
| Studies Count | 82 | 298 |
| Research Status | Pre-clinical | Pre-clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
IGF-1 LR3 Benefits
- ✓Promotes muscle hyperplasia (new muscle cells)
- ✓Extended half-life vs native IGF-1
- ✓Enhanced protein synthesis
- ✓Improved nutrient partitioning
- ✓Anti-catabolic effects
Omentin-1 Dosing
not established|not established
IGF-1 LR3 Dosing
Standard: 20-50 mcg IM post-workout|Advanced: 50-100 mcg IM or SC daily|Cycle: 4-6 weeks on, 4 weeks off
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
IGF-1 LR3 Side Effects
- ⚠Common: Hypoglycemia (dose-dependent), joint pain, water retention
- ⚠Moderate: Gut growth concern (high doses), acromegaly-like symptoms
- ⚠Serious: Theoretical cancer risk (prolonged high-dose use)
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
IGF-1 LR3
IGF-1 LR3 has extensive in vitro and animal data. Its role in muscle hyperplasia is well-documented. The extended half-life modification provides practical advantages over native IGF-1.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.